The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets
Open accessAbstract
The decreasing cost of genomic technologies has enabled the molecular characterization of large-scale clinical disease samples and of molecular changes upon drug treatment in various disease models. Exploring methods to relate diseases to potentially efficacious drugs through various molecular features is critically important in the discovery of new therapeutics. Here we show that the potency of a drug to reverse cancer-associated gene expression changes positively correlates with that drug’s efficacy in preclinical models of breast, liver and colon cancers. Using a systems-based approach, we predict four compounds showing high potency to reverse gene expression in liver cancer and validate that all four compounds are effective in five liver cancer cell lines. The in vivo efficacy of pyrvinium pamoate is further confirmed in a subcutaneous xenograft model. In conclusion, this systems-based approach may be complementary to the traditional target-based approach in connecting diseases to potentially efficacious drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
Inconsistency in large pharmacogenomic studies
Haibe-Kains, B., El-Hachem, N., Birkbak, N. J., Jin, A. C., Beck, A. H., Aerts, H. J. W. L., & Quackenbush, J. (2013) · Nature · doi:10.1038/nature12831 · Cited by 499
Research works printed but not linked: 50
- Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014). · DOI · Paper page
- Hakimi, A. A. et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell 29, 104–116 (2016). · DOI · Paper page
- Zhang, H. et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166, 755–765 (2016). · DOI · Paper page
- Chen, B. & Butte, A. J. Leveraging big data to transform target selection and drug discovery. Clin. Pharmacol. Ther. 99, 285–297 (2015). · DOI · Paper page
- Wilmes, A. et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics 79, 180–194 (2013). · DOI · Paper page
- Abelin, J. G. et al. Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes. Mol. Cell. Proteomics 15, 1622–1641 (2016). · DOI
- Lamb, J. et al. The connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929–1935 (2006). · DOI · Paper page
- Jahchan, N. S. et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov. 3, 1364–1377 (2013). · DOI · Paper page
- van Noort, V. et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res. 74, 5690–5699 (2014). · DOI
- Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011). · DOI · Paper page
- Pessetto, Z. Y. et al. In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget 8, 4079–4095 (2016). · DOI
- Zerbini, L. F. et al. Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Molecular cancer therapeutics 13, 1929–1941 (2014). · DOI
- Dudley, J. T. et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci. Transl. Med. 3, 96ra76 (2011). · DOI · Paper page
- Brum, A. M. et al. Connectivity map-based discovery of parbendazole reveals targetable human osteogenic pathway. Proc. Natl Acad. Sci. USA 112, 12711–12716 (2015). · DOI
- Cheng, J., Yang, L., Kumar, V. & Agarwal, P. Systematic evaluation of connectivity map for disease indications. Genome Med. 6, 540 (2014). · DOI
- Wagner, A. et al. Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Mol. Syst. Biol. 11, 791 (2015). · DOI
- Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W. & Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem.l Biol. 9, 708–714 (2013). · DOI · Paper page
- Demontis, G. C., Ratto, G. M., Bisti, S. & Cervetto, L. Effect of blocking the Na+/K+ ATPase on Ca2+ extrusion and light adaptation in mammalian retinal rods. Biophys. J. 69, 439–450 (1995). · DOI
- Park, K. S. et al. FCCP depolarizes plasma membrane potential by activating proton and Na+ currents in bovine aortic endothelial cells. Pflugers Arch.y 443, 344–352 (2002). · DOI
- Alao, J. P. & Sunnerhagen, P. The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation. Radiat. Oncol. 4, 51 (2009). · DOI
- Xu, W. et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS ONE 8, e71508 (2013). · DOI
- Pez, F. et al. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J. Hepatol. 59, 1107–1117 (2013). · DOI · Paper page
- Lorente-Trigos, A., Varnat, F., Melotti, A. & Ruiz i Altaba, A. BMP signaling promotes the growth of primary human colon carcinomas in vivo. J. Mol. Cell Biol. 2, 318–332 (2010). · DOI
- Li, Y. et al. G protein-coupled estrogen receptor is involved in modulating colonic motor function via nitric oxide release in C57BL/6 female mice. Neurogastroenterol. Motil. 28, 432–442 (2016). · DOI
- Lyu, J. H. et al. RGS2 suppresses breast cancer cell growth via a MCPIP1-dependent pathway. J. Cell. Biochem. 116, 260–267 (2015). · DOI
- Hao, M. W. et al. Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines. World J. Gastroenterol. 8, 203–207 (2002). · DOI
- Tice, D. A., Soloviev, I. & Polakis, P. Activation of the Wnt pathway interferes with serum response element-driven transcription of immediate early genes. J. Biol. Chem. 277, 6118–6123 (2002). · DOI
- Huang, M., Shen, A., Ding, J. & Geng, M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci. 35, 41–50 (2014). · DOI · Paper page
- Neal, J. W. & Sledge, G. W. Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nat. Rev. 11, 627–628 (2014).
- Hoelder, S., Clarke, P. A. & Workman, P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol. Oncol. 6, 155–176 (2012). · DOI · Paper page
- Kidd, B. A. et al. Mapping the effects of drugs on the immune system. Nat. Biotechnol. 34, 47–54 (2016). · DOI
- Iorio, F. et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl Acad. Sci. USA 107, 14621–14626 (2010). · DOI · Paper page
- Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016). · DOI · Paper page
- Yu, D. H. et al. Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS ONE 3, e3951 (2008). · DOI
- Venugopal, C. et al. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells. Clin. Cancer Res. 21, 5324–5337 (2015). · DOI
- Deng, L. et al. Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis. 4, e614 (2013). · DOI
- Hernandez-Vargas, H., Palacios, J. & Moreno-Bueno, G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene 26, 2902–2913 (2007). · DOI
- Niepel, M. et al. Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci. Signal. 6, ra84 (2013). · DOI
- Wei, S. et al. Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Mol. Oncol. 7, 297–307 (2013). · DOI
- Chen, B., Sirota, M., Fan-Minogue, H., Hadley, D. & Butte, A. J. Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research. BMC Med. Genomics 8, (Suppl 2): S5 (2015). · DOI
- Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013). · DOI · Paper page
- Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010). · DOI · Paper page
- Chen, B. et al. Relating chemical structure to cellular response: an integrative analysis of gene expression, bioactivity, and structural data across 11,000 compounds. CPT Pharmacometrics Syst. Pharmacol. 4, 576–584 (2015). · DOI
- Holliday, D. L. & Speirs, V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 13, 215 (2011). · DOI · Paper page
- Lacroix, M. & Leclercq, G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83, 249–289 (2004). · DOI · Paper page
- Chen, Y., Li, Y., Narayan, R., Subramanian, A. & Xie, X. Gene expression inference with deep learning. Bioinformatics 32, 1832–1839 (2016). · DOI · Paper page
- Vidovic, D., Koleti, A. & Schurer, S. C. Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action. Front. Genet. 5, 342 (2014).
- Cheng, J. et al. Evaluation of analytical methods for connectivity map data. Pac. Symp. Biocomput. 2013, 5–16, (2013).
- Duan, Q. et al. L1000CDS2: LINCS L1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 16015 (2016). · DOI · Paper page
- van Westen, G. J., Gaulton, A. & Overington, J. P. Chemical, target, and bioactive properties of allosteric modulation. PLoS Comput. Biol. 10, e1003559 (2014). · DOI
Cited by
Artificial Intelligence in Cancer Research and Precision Medicine
Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0090 · Cited by 781
Phenotypic drug discovery: recent successes, lessons learned and new directions
Vincent, F., Nueda, A., Lee, J., Schenone, M., Prunotto, M., & Mercola, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 348
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres-Martin, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 301
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
“In a separate large scale analysis, Chen et al. analysed >66,000 compound gene expression profiles from the Library of Integrated Network-Based Cellular Signatures L1000 data set (including expression changes of 978 genes in cancer cells after compound treatment), >12 million compound activity measurements from the Ch…”
MethodInfluentialSelf-citationExtending the small-molecule similarity principle to all levels of biology with the Chemical Checker
Duran-Frigola, M., Pauls, E., Guitart-Pla, O., Bertoni, M., Alcalde, V., Amat, D., Juan-Blanco, T., & Aloy, P. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0502-7 · Cited by 126
“The capacity of drugs to revert cancer gene expression profiles correlates with their efficacy 24 and, indeed, using D1 signatures we obtained similar results on the Genomics of Drug Sensitivity in Cancer (GDSC) panel of cancer cell lines 25 (Supplementary Fig.”
BackgroundResult
Metadata
- Authors
- Chen, B., Ma, L., Paik, H., Sirota, M., Wei, W., Chua, M.-S., So, S., & Butte, A. J.
- Venue
- Nature Communications
- Published
- 2017-07-12
- Volume
- 8
- Issue
- 1
- Pages
- 16022-16022
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2734505834
- Cited by
- 215
- References
- 11
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. https://app.cochat.ai/papers/10.1038/ncomms16022
- The paper
- Chen, B., Ma, L., Paik, H., Sirota, M., Wei, W., Chua, M.-S., So, S., & Butte, A. J. (2017). Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nature Communications. https://doi.org/10.1038/ncomms16022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.